A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
Latest Information Update: 30 Sep 2024
At a glance
- Drugs ABBV 1088 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 03 Sep 2024 New trial record